Johnson & Johnson pay a hefty $72 million in Ovarian Cancer case

February 24, 2016

Johnson & Johnson pay a hefty $72 million in Ovarian Cancer case


Do you recall Johnson & Johnson’s Talcum baby powder?

J & J baby powder Cancer LawsuitWell sources tell us that the long time feminine hygienic product is carcinogenic.

Jacqueline Fox, a resident of Birmingham, Alabama died of ovarian cancer at age of 62 in October of last year. Before her demise, Fox claimed to have used Baby Powder and Shower to Shower from Johnson and Johnson for over 35 years prior to being diagnosed with cancer.

Following a 3 week trial and a 4 hour deliberation, the family of Jacqueline Fox were awarded $10 million for actual damages and $62 million for punitive damages by the jurors in the circuit court of St. Louis, per lawyer’s report and court records.

According to the Fox family lawyer Jere Beasley, “Johnson & Johnson were found liable for fraud, negligence and conspiracy. This is the first time for a U.S. jury to award damages over the claims.”

This is not the first time that Johnson and Johnson’s products, particularly talcum baby powder, have been accused of causing wrongful damages or death

Albeit, no damages were awarded, plaintiff Dean Berg’s case of Johnson & Johnson’s baby powder products factoring in her development of ovarian cancer, was acknowledged by a federal jury in Sioux Falls, South Dakota in October of 2013.

During a conference call with journalists, Beasley alleged that Johnson & Johnson were aware of the risk and side effect of their product in the 1980 however, they continued to deceive the public and “lied to regulatory agencies.”

The following statement was released by Johnson & Johnson spokeswoman

Carol Goodrich, “the We have no higher responsibility than the health and safety of consumers, and we are disappointed with the outcome of the trial. We sympathize with the plaintiff’s family but firmly believe the safety of cosmetic talc is supported by decades of scientific evidence.”

Shower to Shower is now a property of Valeant Pharmaceuticals International Inc

Publisher: Salient News